Floatz logo

Human Cd19 Targeted T Cells

Lymphoma

M.D. Anderson Cancer CenterCell therapyPhase 1Dormant
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
65/ 100

Competitive context

243 Active assets in the Lymphoma cohort.

Asset / SponsorPhaseRating
VINBLASTINE
Intensity Therapeutics, Inc.
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
The Lymphoma Academic Research Organisation
Phase 4BBB
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
BLEOMYCIN
Shandong Provincial Hospital
Phase 4BB
FILGRASTIM
M.D. Anderson Cancer Center
Phase 4BB

View all 50 →

Same molecule, other indications

Human Cd19 Targeted T Cells is also rated in:

Advanced CancersDormant
CC
Indicative ·
47 / 100
View asset →
LeukemiaDormant
CC
Indicative ·
44 / 100
View asset →
Blood And Marrow TransplantationDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →